Introduction
sound showed no abnormalities. A renal biopsy showed Thrombotic microangiopathy (TMA) is a known a borderline interstitial rejection according to the Banff complication associated with cyclosporin A (CsA) classification. CsA trough levels were in the therapeutic therapy after renal transplantation, even in patients who range (150-200 mg/l ). The patient was again treated with do not have haemolytic uraemic syndrome (HUS) as 6×1 g methylprednisolone i.v., but renal function their original renal disease [1] . Manifestations caused by improved only marginally and did not return to baseline. the endothelial swelling and microvascular thrombi Two weeks after this treatment, the patient developed a include renal failure and neurological symptoms such as severe vital depression with lethargy, anorexia and sleepheadache, confusion, seizures and coma [2, 3] .
lessness. No focal neurological abnormalities were found. Psychiatric manifestations in the form of severe vital Laboratory investigation showed progressive anaemia depression have not been reported until now. We with a decrease in haemoglobin level from 7.2 to describe two patients with CsA-associated TMA 5.5 mmol/l, thrombocytopenia (50×109/l ), and rising several weeks after transplantation in whom the clinical LDH level (1441 U/l ) (Figure 1 ). In addition, abundant picture was dominated by a severe vital depression schistocytes were found on peripheral blood smear, the without other neurological findings as the sole sign of haptoglobin level was low (<0.1 g/l ) and coagulation possible cerebral localization.
tests were normal. A diagnosis of TMA probably related to CsA was made. Cyclosporin A therapy was discontinued and Case 1 plasmapheresis instituted. During this treatment, the microangiopathic blood changes disappeared rapidly A 54-year-old woman with renal failure caused by chronic and there was a dramatic improvement of the vital pyelonephritis and treated with CAPD since May 1994 depression. Also, renal function improved with a underwent a cadaveric kidney transplantation in decrease of the serum creatinine-level to 145 mmol/l. December 1996. Immunosuppression consisted of CsA Immunosuppression was maintained with mycophenol-(NeoralA, Novartis), mycophenolate mofetil and lowate mofetil and prednisolone. No recurrent episodes dose prednisolone. Renal graft function was good iniof depression of TMA have occurred since. Current tially, but a biopsy-proven interstitial rejection Banff graft function is excellent with a serum creatinine of grade I was diagnosed on day 20. After failure to respond 105 mmol/l and a creatinine clearance of 65 ml/min. to 6×1 g i.v. methylprednisolone, treatment with rabbit antithymocyte immunoglobulin with temporary discontinuation of CsA according to our local protocol was Case 2 instituted. Graft function improved to baseline-level and the patient was discharged in good clinical condition with A 63-year-old woman received a cadaveric kidney a creatinine clearance of 50 ml/min. transplant in February 1997. Renal failure from medulTwo months later she was readmitted with bronchitis lary polycystic disease and hypertension had led to the and sinusitis with fever up to 39°C. The serum creatinine initiation of CAPD treatment in November 1994, level had risen from 130 to 265 mmol/l. The maxillary which was changed to haemodialysis in May 1996. sinuses were drained and therapy with amoxycillin/clavul-Immunosuppression consisted of CsA (NeoralA, anic acid was instituted. Sputum and sinus-fluid cultures Novartis) and low-dose prednisolone. Delayed graft function necessitating haemodialysis treatment post-operative day. Since there was no response to 6×1 g of i.v. methylprednisolone, treatment with (80×109/l ) developed and LDH was slightly elevated at 600 U/l, but renal function improved to a serum rabbit antithymocyte immunoglobulin was instituted. According to our local protocol CsA therapy was creatinine of 200 mmol/l. One week after restarting CsA, the patient developed a vital depression with discontinued during antithymocyte immunoglobulin treatment. Renal function improved, but recovery was lethargy, anorexia and sleeplessness. Cyclosporin A serum trough levels were in the therapeutic range unsatisfactory with a serum creatinine of 300 mmol/l.
Subsequently the patient suffered from a secondary (150-200 mg/l ). No focal neurological abnormalities were found. Laboratory investigation showed progress-CMV infection with fever and leukopenia, which was successfully treated with i.v. ganciclovir (Figure 2 ). ive anaemia with a drop in haemoglobin level from 7.4 to 5.0 mmol/l, a further decline in platelet count During treatment with ganciclovir, thrombocytopenia (30×109/l ), rising LDH level up to 1142 U/l, a low to the development of TMA. Furthermore, a period of infection with H. influenzae (first patient) and CMV haptoglobin level (<0.1 g/l ), and normal coagulation tests. In addition, a second renal biopsy showed signs of (second patient) was present shortly before TMA became clinically evident. In line with the idea that microvascular thrombosis and glomerular mesangiolysis besides a borderline interstitial rejection accord-post-transplant cyclosporin-A-related TMA is of multifactorial origin is the finding by Noël et al. [12] that ing to the Banff classification. A diagnosis of TMA was made and CsA therapy was discontinued. Rapid as many as 25% of renal transplant patients treated with CsA on close laboratory monitoring show signs and impressive improvement of the depressive symptoms occurred. Moreover, significant improvement of of microangiopathic haemolytic anaemia, mostly without clinical signs, especially following a CMV infection renal function (serum creatinine 95 mmol/l ), accompanied by normalization of other laboratory para-or rejection episode.
The most striking finding in our two patients was meters including the platelet count and haptoglobin level was seen. Immunosuppression was continued with the occurrence of severe vital depression without focal neurological signs as the main symptom of their TMA. mycophenolate mofetil and prednisolone without recurrence of TMA or depression.
Both patients showed impressive improvement of their mental state coinciding with the remission of the microangiopathic haemolytic changes. Therefore isolated mental changes occurring during CsA therapy
Discussion
should lead to consideration of TMA as a possible cause and to appropriate laboratory investigations to TMA is a known complication associated with CsA detect or exclude this possibility. in renal transplant recipients who do not have HUS as Surgery 1985; 98: 54-62 their original disease, de novo TMA occurs [1, 7] . Up to
